<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01665092</url>
  </required_header>
  <id_info>
    <org_study_id>GM103799</org_study_id>
    <nct_id>NCT01665092</nct_id>
  </id_info>
  <brief_title>Rapid Administration of Carnitine in sEpsis</brief_title>
  <acronym>RACE</acronym>
  <official_title>Phase 2 Study of Levo-Carnitine for Vasopressor Dependent Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Mississippi Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Mississippi Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prior work has shown that exogenous L-carnitine administration enhances glucose and lactate
      oxidation, attenuates fatty acid toxicity, and improves endothelial-smooth muscle coupling
      and cardiac mechanical efficiency. The overall goal of this proposal is to investigate
      L-carnitine as a novel adjunctive treatment of septic shock. In this study the investigators
      will test our primary hypothesis: Early adjunctive L-carnitine administration in vasopressor
      dependent septic shock will significantly reduce cumulative organ failure at 48 hours with an
      associated decrease in 28-day mortality suggesting the need for further phase III study. To
      accomplish this the investigators will conduct a phase II, double blinded, placebo
      controlled, adaptive randomized trial of 250 eligible patients with vasopressor-dependent
      septic shock. Study subjects will be assigned to one of four arms: low (6g), medium (12g) or
      high (18g) dose intravenous L-carnitine or placebo for 12 hours as a part of early
      resuscitative care.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Actual">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>delta SOFA</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 day</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carnitine Low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levo-Carnitine 6g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carnitine Medium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levo-Carnitine 12 g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carnitine High</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levo-Carnitine 18 g</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levo-Carnitine</intervention_name>
    <arm_group_label>Carnitine Low</arm_group_label>
    <arm_group_label>Carnitine Medium</arm_group_label>
    <arm_group_label>Carnitine High</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Suspected or confirmed infection (examples include but are not limited to: white cells
             in a normally sterile body fluid; perforated viscus; radiographic evidence of
             pneumonia in clinical symptoms; a syndrome associated with a high risk of infection
             e.g. cellulitis, cutaneous abscess, ascending cholangitis, toxic shock syndrome, fever
             of unknown origin with high suspicion of infectious etiology)

          2. Any two of four criteria of systemic inflammatory response as defined by the 2001
             ACCP/SCCM Consensus Conference Committee;

          3. Recognition of septic shock and initiation of quantitative resuscitation within 24
             hours of enrollment;

          4. Requirement of high dose vasopressors for ≥4 hours to treat shock: Norepinephrine &gt;
             0.05mcg/kg/min; dopamine &gt;10mcg/kg/min; Phenylephrine &gt;0.4 mcg/kg/min; epinephrine &gt;
             0.05 mcg/kg/min;

          5. Cumulative sequential organ failure assessment (SOFA) score of ≥ 6;

          6. Blood lactate level of &gt;2.0 mMol/L.

        Exclusion Criteria:

          1. Age &lt;18 years;

          2. Pregnancy or breastfeeding;

          3. Any primary diagnosis other than sepsis;

          4. Established Do Not Resuscitate status or advanced directives restricting aggressive
             care or treating physician deems aggressive care unsuitable;

          5. Any history of seizures or a known seizure disorder;

          6. Any known inborn error of metabolism;

          7. Anticipated requirement for surgery that would interfere with the 12 hour infusion
             time;

          8. Active participation in another interventional study;

          9. Cardiopulmonary resuscitation (chest compression or defibrillation) prior to
             enrollment;

         10. Known systemic allergy to L-carnitine.

         11. Severe immunocompromised state (e.g. subject has neutropenia [receiving cytotoxic
             chemotherapy with absolute neutrophil count &lt;500/uL or expected to decline to &lt; 500 uL
             within the next three days).

         12. Active Treatment with Coumadin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Jones, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Mississippi Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univeristy of California Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health Services</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BIDMC</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BWH</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MGH</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>29316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2012</study_first_submitted>
  <study_first_submitted_qc>August 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2012</study_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Mississippi Medical Center</investigator_affiliation>
    <investigator_full_name>Alan Jones</investigator_full_name>
    <investigator_title>Professor of Emergency Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

